MedPath

A Multi-center Prospective Cohort Study Based on Peritoneal Dialysis Telemedicine-assisted Platform

Recruiting
Conditions
Peritoneal Dialysis
Registration Number
NCT03571451
Lead Sponsor
Peking University First Hospital
Brief Summary

Increasing the proportion of patients on peritoneal dialysis (PD) may relieve the financial burden caused by the growing number of patients with end-stage renal disease (ESRD). The investigators are developing a PD database in China using peritoneal dialysis telemedicine-assisted platform (PD TAP). The survival rate and technique survival rate of PD patients, as well as risk factors associated with survival and technique survival will be analyzed through PD TAP.

Detailed Description

The growing number of patients with ESRD leads to an increasing medical burden all around the world. Patients on PD have a similar long-term survival rate as patients on hemodialysis, with a much lower cost of medical resources. Therefore, increasing the percentage of patients on PD may relieve the increasing financial burden for the whole society.

Of note, technique survival and patient survival in PD still need to be improved. Based on results from multi-center cohort studies, some prognostic factors have been explored and intervened in recent years. However, robust data from large samples on potential predictors pertaining to patients' clinical characteristics, and PD practice on clinical outcomes in the real world is still limited. This phenomenon calls an action on exploring novel risk factors of patient outcome, especially through national-level prospective cohort study.

The investigators are developing a national-level PD database by registering all patients receiving PD on PD TAP. The study is underway in 27 hospitals from 14 provinces located at 7 geographical regions (northwest, northeast, north, central, southwest, southeast and south) in China. National samples of PD units are recruited based on the availability of professional PD team who is willing participant and could regularly follow participants. Our study aims to enroll adult 7,000 patients with end stage renal disease receiving PD. Patients-, treatment- and telemedicine-level variables are collected at baseline and thus at 3-month intervals. PD practice surveys are collected at baseline. All-cause mortality and transfer to hemodialysis will be recorded as primary outcomes. Other clinical outcomes including infectious and non-infectious complications would be recorded. Apart from the above objectives, potential collaboration between PDTAP and local or international clinical research could develop ancillary studies with specific aims. Examples of key research and ancillary investigation proposed in PDTAP study are as follows: 1) Long-term effects of telemedicine on clinical outcomes of patients on PD: a propensity matched study, 2) Anemia, erythrocyte-stimulating agents, inflammation and the association with mortality in patients on PD, 3) The management of serum calcium, phosphate, and hyperparathyroidism and its relationship with mortality in patients on PD, 4) The prevalence of hypomagnesemia, and all-cause and cardiovascular mortality in patients on PD, 5) The prevalence, predictors, and outcomes of PD-related peritonitis, 6) Association between hemoglobin levels and serum albumin levels and mortality in diabetic and non-diabetic patients on PD, 7) Glucose absorption (measured as the difference between the amount of glucose in peritoneal dialysate absorbed into the peritoneal cavity in 24h and that measured in the 24h drained effluent) and its association with metabolic syndrome, cardiovascular events, and mortality in patients on PD. The follow-up will be continued until the end of the study.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
7000
Inclusion Criteria
  • End-stage renal disease patients receiving maintenance peritoneal dialysis;
  • more than 14 years old
Exclusion Criteria
  • receiving temporary PD due to acute kidney injury
  • loss to follow up without any outcomes recorded.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
All-cause death10 years

All-cause death refers to the number of patients who died within the anticipated time frame. For example death caused by CVD, systemic infection, malignancies (according to the WHO classification), and protein-energy wasting.

Transfer to hemodialysis10 years

Transfer to hemodialysis refers to the number of patients who were Transfer to hemodialysis from PD due to any cause within the anticipated time frame. For example, caused by dialysis inadequacy, volume overload, infection-related (peritonitis and exitsite infection), catheter dysfunction (catheter blockage and displacement), ultrafiltration failure, et al.

Secondary Outcome Measures
NameTimeMethod
Exit-site/tunnel infection10 years

The incidence of exit-site/tunnel infection during the time frame. Includes organism-specific, infection-related death or transfer to hemodialysis.

others10 years

The incidence of other complications during the time frame, such as new-onset diabetes/cancer, and encapsulating peritoneal sclerosis.

Other causes for terminating PD10 years

The incidence of other causes for terminating PD during the time frame. For example, caused by kidney transplantation, burnout, caretaker burnout or absence physical handicap preventing self-care.

Peritonitis10 years

The incidence of peritoneal dialysis related peritonitis during the time frame. Includes first-episode/multi-episode, refractory, relapsing, repeat, and recurrent, organism-specific, peritonitis-related death or transfer to hemodialysis.

Cardiovascular events10 years

The incidence of cardiovascular events during the time frame. For example, caused by congestive heart failure, angina or acute myocardial infarction, cerebrovascular accident, and peripheral arterial events.

Abdominal wall complications10 years

The incidence of abdominal wall complications occurred during the time frame, such as peritoneal leaks and hernia.

Trial Locations

Locations (27)

The second affiliated hospital of Harbin Medical University

🇨🇳

Harbin, Heilongjiang, China

Pingdingshan People's Hospital No.1

🇨🇳

Pingdingshan, Henan, China

First affiliated hospital of Zhengzhou University

🇨🇳

Zhengzhou, Henan, China

The first affiliated hospital of Baotou Medical College

🇨🇳

Baotou, Inner Mongolia, China

The first hospital of Jilin University

🇨🇳

Changchun, Jilin, China

Shengjing hospital affiliated to China Medical University

🇨🇳

Liaoyang, Liaoning, China

People's Hospital of Gansu Province

🇨🇳

Lanzhou, Gansu, China

Cangzhou central hospital

🇨🇳

Cangzhou, Hebei, China

Taiyuan central hospital

🇨🇳

Taiyuan, Shanxi, China

The second hospital of Shanxi Medical University

🇨🇳

Taiyuan, Shanxi, China

People's hospital of Cangzhou

🇨🇳

Cangzhou, Hebei, China

Beijing haidian hospital

🇨🇳

Beijing, China

People's hospital of Langfang

🇨🇳

Langfang, Hebei, China

The second hospital of Hebei medical university

🇨🇳

Shijiazhuang, Hebei, China

People's Hospitel of Qinghai Province

🇨🇳

Xining, Qinghai, China

Xinqiao hospital of the Third Military Medical University

🇨🇳

Chongqing, China

Beijing miyun district hospital

🇨🇳

Beijing, China

The second affiliated hospital of Anhui Medical University

🇨🇳

Hefei, Anhui, China

Peking University Shenzhen Hospital

🇨🇳

Shenzhen, Guangdong, China

Handan Central Hospital

🇨🇳

Handan, Hebei, China

The third hospital of Hebei Medical University

🇨🇳

Shijiazhuang, Hebei, China

The first people's hospital of Xining

🇨🇳

Xining, Qinghai, China

The People's Hospital of Chuxiong Yi Autonomous Prefecture

🇨🇳

Chuxiong, Yunnan, China

Beijing Charity Hospital

🇨🇳

Beijing, China

Beijing dongzhimen Hospital

🇨🇳

Beijing, China

Peking University People's Hospital

🇨🇳

Beijing, China

Peking University First Hospital

🇨🇳

Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath